Volume 67, Issue 4 pp. 589-597

Growth hormone (GH) secretion and response to GH therapy after total body irradiation and haematopoietic stem cell transplantation during childhood

B. Bakker

B. Bakker

Department of Paediatrics, Leiden University Medical Centre, Leiden, the Netherlands,

Search for more papers by this author
W. Oostdijk

W. Oostdijk

Department of Paediatrics, Leiden University Medical Centre, Leiden, the Netherlands,

Search for more papers by this author
R. B. Geskus

R. B. Geskus

Department of Medical Statistics, Leiden University Medical Centre, Leiden, the Netherlands,

Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, the Netherlands

Search for more papers by this author
W. H. Stokvis-Brantsma

W. H. Stokvis-Brantsma

Department of Paediatrics, Leiden University Medical Centre, Leiden, the Netherlands,

Search for more papers by this author
J. M. Vossen

J. M. Vossen

Department of Paediatrics, Leiden University Medical Centre, Leiden, the Netherlands,

Search for more papers by this author
J. M. Wit

J. M. Wit

Department of Paediatrics, Leiden University Medical Centre, Leiden, the Netherlands,

Search for more papers by this author
First published: 30 May 2007
Citations: 24
B. Bakker, Department of Paediatrics, Reinier de Graaf Gasthuis, PO Box 5011, 2600 GA, Delft, the Netherlands. Tel: +31-15-260 3060; Fax: +31–15 2603559; E-mail: [email protected]

Summary

Objective In January 1997 we introduced a protocol for the treatment with GH of children with impaired growth after unfractionated total body irradiation (TBI). This study is an evaluation of that protocol.

Patients and methods Between January 1997 and July 2005, 66 patients (48 male) treated for haematological malignancies had at least two years of disease-free survival after TBI-based conditioning for stem cell transplantation (SCT). Stimulated and/or spontaneous GH secretion was decreased in 8 of the 29 patients tested because of impaired growth. Treatment with GH (daily dose 1·3 mg/m2 body surface area) was offered to all 29 patients and initiated in 23 of them (17 male). The main outcome measure was the effect of GH therapy on height standard deviation scores (SDS) after onset of GH therapy, estimated by random-effect modelling with corrections for sex, age at time of SCT and puberty (data analysed on intention-to-treat basis).

Results At time of analysis, median duration of therapy was 3·2 years; median follow-up after start of GH therapy was 4·2 years. The estimated effect of GH therapy, modelled as nonlinear (logit) curve, was +1·1 SD after 5 years. Response to GH therapy did not correlate to GH secretion status.

Conclusion GH therapy has a positive effect on height SDS after TBI, irrespective of GH secretion status.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.